ArticleBMC cancer2019
Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Transarterial chemoembolization with 125 I seed insertion for unresectable hepatocellular carcinoma: a meta‑analysis.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2025Pooled it
- Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis.Frontiers in oncology · 2024Pooled it
- Radiofrequency ablation versus laparoscopic hepatectomy for treatment of hepatocellular carcinoma: a systematic review and meta-analysis.World journal of surgical oncology · 2020Pooled it
- Transarterial chemoembolization with radioactive seed implantation for multitumor hepatocellular carcinoma.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2026Article
- Outcomes of transarterial chemoembolization plus percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma with tumor diameter > 3 cm versus ≤ 3 cm: a single-center retrospective study.Frontiers in oncology · 2026Article
- Long-term efficacy of transarterial chemoembolization in the treatment of recurrent hepatocellular carcinoma.BMC gastroenterology · 2025Article
- Proton Beam Therapy Provides Longer Survival and Preserves Muscle Mass in Hepatocellular Carcinoma Compared to TACE+RFA.Cancers · 2025Article
- Combining transarterial chemoembolization, radiofrequency ablation, and iodine-125 seed implantation for recurrent hepatocellular carcinoma post-hepatectomy.Diagnostic and interventional radiology (Ankara, Turkey) · 2025Article
- Survival Benefits of Transarterial Chemoembolization Plus Ablation Therapy in Patients With Intermediate or Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.Cancer management and research · 2025Article
- Drug-eluting bead transarterial chemoembolization combined with apatinib/camrelizumab for the treatment of advanced hepatocellular carcinoma with hepatic arterioportal shunts.The British journal of radiology · 2024Article
- The combination of transarterial chemoembolization and microwave ablation is superior to microwave ablation alone for liver metastases from colorectal cancer.Journal of cancer research and clinical oncology · 2024Article
- Microwave ablation followed by cTACE in 5-cm HCC lesions: does a single-session approach affect liver function?La Radiologia medica · 2024Article
- Melatonin enhances the efficacy of anti-PD-L1 by improving hypoxia in residual tumors after insufficient radiofrequency ablation.Journal of pharmaceutical analysis · 2024Article
- Article
- Radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma meeting Milan criteria: a focus on tumor progression and recurrence patterns.Frontiers in oncology · 2024Article
- RAD21: A Key Transcriptional Regulator in the Development of Residual Liver Cancer.Journal of hepatocellular carcinoma · 2024Article
- Transarterial chemoembolization with insertion of radioactive seeds for hepatocellular carcinoma.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2023Article
- Radiofrequency ablation of hepatocellular carcinoma: Current status, challenges, and prospects.Liver research (Beijing, China) · 2023Review
- Longer Survival and Preserved Liver Function after Proton Beam Therapy for Patients with Unresectable Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2023Article
- Establishment and validation of a predictive model of recurrence in primary hepatocellular carcinoma after resection.Journal of gastrointestinal oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundTo determine the safety and efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (hereafter, TACE-RFA) in treating Barcelona Clinic Liver Cancer (BCLC) Stage A or B (hereafter, BCLC A/B) hepatocellular carcinoma (HCC) patients, and to explore the range of tumor sizes suitable for combination therapy.
methodsThis retrospective study assessed the consecutive medical records of HCC patients with BCLC A/B who received TACE-RFA or TACE from September 2009 to September 2018. Progression-free survival (PFS), overall survival (OS), therapeutic response, and complications were compared between the two groups.
resultsAmong 2447 patients who received TACE-RFA or TACE, 399 eligible patients were enrolled in our study, including 128 patients in the TACE-RFA group and 271 patients in the TACE group. Compared with the TACE group, the PFS and OS rates of 1,3,5,8 years in the TACE-RFA group were significantly better, with higher objective tumor regression rate and better disease control rate. RFA treatment did not increase the risk of death in patients with HCC, and both liver subcapsular hematoma and bile duct injury were improved by symptomatic treatment. Serum α-fetoprotein level and treatment method were important independent prognostic factors for OS, whereas albumin, hepatitis B and treatment method were important independent prognostic factors for PFS. Subgroup analysis showed that patients in the TACE-RFA group always showed better OS and PFS.
conclusionsTACE-RFA had an advantage over TACE alone in prolonging PFS and improving OS in HCC patients with BCLC A/B, and can benefit patients regardless of tumor size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.